Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866 74. S7.9.1.1-36. Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome: an international multicenter study. Circulation. 2016;134:872 82. S7.9.1.1-37. Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD: true or false? Heart Rhythm. 2009;6:113 20. S7.9.1.1-38. Garson A Jr, Dick M, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation. 1993;87:1866 72. S7.9.1.1-39. Priori SG, Bossaert LL, Chamberlain DA, et al. ESC-ERC recom- mendations for the use of automated external defibrillators (AEDs) in Europe. Eur Heart J. 2004;25:437 45. S7.9.1.1-40. Steinberg C, Padfield GJ, Al-Sabeq B, et al. Experience with bisoprolol in long-QT1 and long-QT2 syndrome. J Interv Card Electrophysiol. 2016;47:163 70. S7.9.1.1-41. Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-block- ers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012;60:2092 9. S7.9.1.1-42. Khositseth A, Tester DJ, Will ML, et al. Identification of a com- mon genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm. 2004;1: 60 4. S7.9.1.1-43. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syn- drome. LQTS Investigators. Circulation. 1998;97:451 6. S7.9.1.1-44. Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation. 1999;100:2431 6. S7.9.1.1-45. Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta- adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol. 1992;20:830 7. S7.9.1.1-46. Moss AJ, Liu JE, Gottlieb S, et al. 